Schulman KA - Search Results

1

Options to Promote Competitive Generics Markets in the United States.

Wiske CP, Ogbechie OA, Schulman KA. Wiske CP, et al. Among authors: schulman ka. JAMA. 2015 Nov 24;314(20):2129-30. doi: 10.1001/jama.2015.13498. JAMA. 2015. PMID: 26513309 No abstract available.

2

Economic return of clinical trials performed under the pediatric exclusivity program.

Li JS, Eisenstein EL, Grabowski HG, Reid ED, Mangum B, Schulman KA, Goldsmith JV, Murphy MD, Califf RM, Benjamin DK Jr. Li JS, et al. Among authors: schulman ka. JAMA. 2007 Feb 7;297(5):480-8. doi: 10.1001/jama.297.5.480. JAMA. 2007. PMID: 17284698 Free PMC article.

3

Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death.

Curtis LH, Al-Khatib SM, Shea AM, Hammill BG, Hernandez AF, Schulman KA. Curtis LH, et al. Among authors: schulman ka. JAMA. 2007 Oct 3;298(13):1517-24. doi: 10.1001/jama.298.13.1517. JAMA. 2007. PMID: 17911496

4

Changes in the use and costs of diagnostic imaging among Medicare beneficiaries with cancer, 1999-2006.

Dinan MA, Curtis LH, Hammill BG, Patz EF Jr, Abernethy AP, Shea AM, Schulman KA. Dinan MA, et al. Among authors: schulman ka. JAMA. 2010 Apr 28;303(16):1625-31. doi: 10.1001/jama.2010.460. JAMA. 2010. PMID: 20424253

5

A cautious path forward on accountable care organizations.

Richman BD, Schulman KA. Richman BD, et al. Among authors: schulman ka. JAMA. 2011 Feb 9;305(6):602-3. doi: 10.1001/jama.2011.111. JAMA. 2011. PMID: 21304085 No abstract available.

6

Reassessing ACOs and Health Care Reform.

Schulman KA, Richman BD. Schulman KA, et al. JAMA. 2016 Aug 16;316(7):707-8. doi: 10.1001/jama.2016.10874. JAMA. 2016. PMID: 27533151 No abstract available.

7

Financing and Distribution of Pharmaceuticals in the United States.

Dabora MC, Turaga N, Schulman KA. Dabora MC, et al. Among authors: schulman ka. JAMA. 2017 Jul 4;318(1):21-22. doi: 10.1001/jama.2017.5607. JAMA. 2017. PMID: 28505252 No abstract available.

8

PCSK9 Inhibitors and the Choice Between Innovation, Efficiency, and Affordability.

Mark DB, Schulman KA. Mark DB, et al. Among authors: schulman ka. JAMA. 2017 Aug 22;318(8):711-712. doi: 10.1001/jama.2017.8907. JAMA. 2017. PMID: 28829851 No abstract available.

9

Administrative Costs Associated With Physician Billing and Insurance-Related Activities at an Academic Health Care System.

Tseng P, Kaplan RS, Richman BD, Shah MA, Schulman KA. Tseng P, et al. Among authors: schulman ka. JAMA. 2018 Feb 20;319(7):691-697. doi: 10.1001/jama.2017.19148. JAMA. 2018. PMID: 29466590 Free PMC article.

10

The Evolving Pharmaceutical Benefits Market.

Schulman KA, Richman BD. Schulman KA, et al. JAMA. 2018 Jun 12;319(22):2269-2270. doi: 10.1001/jama.2018.4269. JAMA. 2018. PMID: 29625496 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

420 results

Search Page

Filters